AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration.

[1]  P. Campochiaro,et al.  Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial , 2017, The Lancet.

[2]  I. Constable,et al.  Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration , 2016, EBioMedicine.

[3]  Glenn J Jaffe,et al.  Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. , 2016, Ophthalmology.

[4]  Ian J Constable,et al.  Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial , 2015, The Lancet.

[5]  J. Flannery,et al.  Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates , 2014, Gene Therapy.

[6]  P. Campochiaro,et al.  Sustained delivery of a HIF-1 antagonist for ocular neovascularization. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[7]  W. Freeman,et al.  HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.

[8]  Michael J. Castle,et al.  Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey , 2011, Science Translational Medicine.

[9]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[10]  P. Campochiaro,et al.  Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells , 2010, Journal of cellular physiology.

[11]  James M. Wilson,et al.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. , 2009, The Journal of infectious diseases.

[12]  P. Campochiaro,et al.  Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels , 2008, Journal of cellular physiology.

[13]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[14]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[15]  P. Campochiaro,et al.  Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. , 2006, Human gene therapy.

[16]  I. Constable,et al.  Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  K. Jooss,et al.  Stable antibody expression at therapeutic levels using the 2A peptide , 2005, Nature Biotechnology.

[18]  M. Capogrossi,et al.  Marked inhibition of retinal neovascularization in rats following soluble‐flt‐1 gene transfer , 2004, The journal of gene medicine.

[19]  P. Campochiaro,et al.  Intraocular expression of endostatin reduces VEGF‐induced retinal vascular permeability, neovascularization, and retinal detachment , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  P. Campochiaro,et al.  Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization , 2003, Gene Therapy.

[21]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Campochiaro,et al.  AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. , 2002, Investigative ophthalmology & visual science.

[23]  R. Ali,et al.  Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1 , 2002, Gene Therapy.

[24]  P. Campochiaro,et al.  Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. , 2002, The American journal of pathology.

[25]  J. Slakter,et al.  RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION , 2001, Retina.

[26]  Y. Tsao,et al.  Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. , 2001, Investigative ophthalmology & visual science.

[27]  P. Campochiaro,et al.  Pigment epithelium‐derived factor inhibits retinal and choroidal neovascularization , 2001, Journal of cellular physiology.

[28]  H. Ueno,et al.  Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration , 2000, Gene Therapy.

[29]  P. Campochiaro,et al.  Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. , 1997, The American journal of pathology.

[30]  Peter K. Kaiser,et al.  ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .

[31]  P. Campochiaro,et al.  Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. , 1998, Investigative ophthalmology & visual science.